Alyson J Berliner Selected Research

aflibercept

4/2022	Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
9/2021	Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
1/2020	Outcomes in Patients with Diabetic Macular Edema Requiring Cataract Surgery in VISTA and VIVID Studies.
1/2019	Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study.
1/2019	Difference in Treatment Effect Between Intravitreal Aflibercept Injection and Laser by Baseline Factors in Diabetic Macular Edema.
1/2019	Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
1/2018	Impact of Baseline Characteristics on Treatment Response to Intravitreal Aflibercept Injection for Wet Age-Related Macular Degeneration.
1/2018	Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
7/2017	Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study.
2/2017	Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alyson J Berliner Research Topics

Disease

22	Macular Edema 09/2021 - 09/2011
11	Macular Degeneration (Age-Related Maculopathy) 01/2019 - 11/2009
9	Retinal Vein Occlusion 02/2016 - 05/2012
8	Diabetic Retinopathy (Retinopathy, Diabetic) 04/2022 - 09/2011
3	Choroidal Neovascularization 01/2019 - 11/2009
2	Hypertension (High Blood Pressure) 01/2019 - 08/2012
2	Inflammation (Inflammations) 12/2012 - 11/2009
1	Cataract (Cataracts) 01/2020
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2019
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2019
1	Pneumonia (Pneumonitis) 03/2015
1	Stroke (Strokes) 03/2015
1	Vitreous Hemorrhage 07/2014
1	Eye Pain 01/2014
1	Eye Hemorrhage 08/2012
1	Nausea 08/2012
1	Pain (Aches) 08/2012
1	Hyperemia 08/2012
1	Heart Failure 08/2012

Drug/Important Bio-Agent (IBA)

33	afliberceptIBA 04/2022 - 11/2009
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2021 - 11/2009
6	Retinaldehyde (Retinal)IBA 01/2020 - 08/2012
3	Ranibizumab (Lucentis)FDA Link 01/2019 - 12/2012
3	salicylhydroxamic acid (SHAM)IBA 11/2014 - 03/2013
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 09/2017
1	Pharmaceutical PreparationsIBA 01/2016
1	Biological ProductsIBA 06/2011
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2009
1	Immunoglobulin G (IgG)IBA 11/2009
1	Proteins (Proteins, Gene)FDA Link 11/2009

Therapy/Procedure

14	Lasers (Laser) 01/2020 - 09/2011
6	Light Coagulation 02/2017 - 09/2011
5	Injections 09/2021 - 03/2013
3	Therapeutics 09/2021 - 02/2017
3	Intravitreal Injections 12/2012 - 11/2009
1	Glycemic Control 09/2017
1	Retreatment 12/2012
1	Intraocular Injections 11/2009